The COVID-19 pandemic continues to spread, and in our commitment to provide transparency to our stakeholders, I want to share an update on our clinical trials.
It was decided to pause enrollment into the filgotinib trials in order to help protect patient safety. This includes the Phase 2 and Phase 3 trials of filgotinib in Crohn’s disease (DIVERSITY), the Phase 3 in psoriatic arthritis (PENGUIN), the Phase 2 trial in uveitis, and the MANTA and MANTA-RAy trials.
We anticipate the Phase 3 program in ankylosing spondylitis will now start later this year.
This does not impact the Phase 3 SELECTION program in ulcerative colitis, as this study is fully enrolled, and we still expect results in the second quarter of this year.
I want to assure you that the Galapagos team continues to face this unprecedented situation with resilience. And as challenging as the COVID-19 crisis is, this too shall pass. Supported by a strong balance sheet, I firmly believe that we can weather this storm. This also comes with a responsibility that we do not take lightly: we are more determined than ever in our unwavering ambition to bring innovation to patients worldwide.
Wishing you all the very best in these difficult times,
Onno van de Stolpe